Diethylstilbestrol :

Diethylstilbestrol
DES Daughters
DES Sons
DES Victims
Back to Defective Drugs

Main Navigation:

Home
About Health Dangers
Contact Us

Subscribe to our Newsletter
for news and updates.


 

Diethylstilbestrol (DES)

DES

DES, or diethylstilbestrol, is a synthetic version of estrogen, a common female hormone. Beginning in the mid-to-late 1940s, Diethylstilbestrol (DES) was prescribed to pregnant women at high risk for miscarriage and other serious pregnancy complications. DES was later found to not only be ineffective at preventing miscarriages, but harmful to fetuses under five months old. In 1971, after an FDA recall, doctors stopped prescribing DES to pregnant wome. In the U.S. an estimated 5 to 10 million persons were exposed to DES from 1938 to 1971, including pregnant women prescribed DES and their children.

DES is still on the market, but is no longer prescribed for pregnant or nursing women. It is used to treat symptoms resulting from menopause, menstrual disorders, postpartum breast enlargement, primary ovarian failure and chemotherapy for advanced breast and prostate cancer.

DES Exposure

If you were exposed to DES, it is imperative you visit your doctor immediately to determine if your exposure is affecting your health. If you are a DES daughter, you will most likely be given a thorough pelvic exam. You should check to make sure your doctor is familiar with the possible problems associated with DES exposure, since some problems such as clear cell adenocarcinoma are likely to be found only when the doctor is looking for them.

If you are a woman who took DES while pregnant, you should inform your doctor. You should try to learn the dosage, when the medication was started, and how it was used. You also should inform your children who were exposed to DES before birth so that this information can be included in their medical records. DES-exposed mothers should have regular breast cancer screening and yearly medical checkups that include a pelvic examination and a Pap test.

Men who were exposed to DES should inform their physician of their exposure and be examined periodically. While the level of risk of developing testicular cancer is unclear among DES-exposure sons, males with undescended testicles or unusually small testicles have an increased risk of developing testicular cancer, whether or not they were exposed to DES.


Diethylstilbestrol - DES

Disclaimer